Coxem코셈

Coxem is loss-making on a trailing basis and its shares have risen sharply, but the filings flag disclosure-related issues.

Coxem, a Korean maker of scanning electron microscopes and related equipment, reported trailing twelve-month revenue of ₩12.6B and an operating loss of ₩2.2B to H1 2026. Its shares closed at ₩9,290 on 16 October 2026, up 53.3% over one month and 26.9% over one year, with a market capitalisation of about ₩50.5B. The data does not include news headlines or analyst views to explain the recent move.

What stands out

• Revenue has declined from ₩14.7B in 2024 to ₩13.4B in 2025, and trailing revenue to H1 2026 is ₩12.6B.
• The company moved from a ₩1.7B net profit in 2023 and ₩1.0B in 2024 to losses in 2025 (₩0.65B net loss) and H1 2026 (₩0.93B net loss on a trailing basis).
• Trailing free cash flow is negative at about ₩1.7B, while cash is ₩1.6B and no borrowings are reported.
• The filings list a notice of planned designation as an unfaithful disclosure company (April 2026) and a later non-designation decision (May 2026), along with several shareholder and trust-related reports.
• Foreign ownership is 6.6%, and the 20-day flows in the data are net foreign selling and net retail buying.

What to watch

• The next quarterly and annual results, to see whether operating losses narrow from the trailing ₩2.2B.
• Any further exchange disclosure decisions or filings, given the disclosure-compliance notices in 2026.
• Share cancellation and trust contract outcomes, and the upcoming investor relations event, as the data gives no detail on their effect.